| EN

Enlength®:Bortezomib for injection

Enlength®:Bortezomib for injection


Used for the treatment of patients with multiple myeloma and mantle cell lymphoma


Multiple myeloma (MM) is a proliferative hematological malignancy that is most prevalent among the elderly. In China, the incidence of MM is higher than acute leukemia, ranking the second among hematological malignancies.

Bortezomib is a proteasome inhibitor that can directly inhibit degradation of proteins by the 26S-proteasome, thereby inhibiting the expression of genes related to cell proliferation and ultimately inducing apoptosis of tumor cells. Its working mechanism won the 2004 Nobel Prize in Chemistry and the 2006 Prix Galien Award the highest honor in the pharmaceutical industry.

As a cornerstone drug for the treatment of multiple myeloma, Bortezomib is used throughout the induction, consolidation and maintenance therapies for myeloma. In 2017, Bortezomib was recommended as a first-line drug for the full management of multiple myeloma in the Guide lines for Diagnosis and Treatment of Multiple Myeloma in China and was included in the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance.